Biopharm company Jennerex nabs $8.3M
Jennerex, a biopharmaceutical treatment developer focused on cancer, brought in $8.3 million earlier this month from various investors, including Calvin Stiller and Korea-based Green Cross Corp. The company has raised about $18 million so far, according to VentureWire.
Headquartered in San Francisco, Jennerex plans to apply the funds over the next 18 months to advance research on a series of drug candidates, conducting testing on liver and eventually colon and lung cancer. It will pursue funding again next year to pay for a new phase of trials that could cost upwards of $30 or $40 million.
Next Story: SpaceX finally gets a rocket into space
Previous Story: Foundry invests in Pie for easier home networking
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.